Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.57 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MDM4 | O15151 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylamine SCHEMBL11263676 | 0.94 | L3MBTL1 (0.57) | L3MBTL1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL3407381 | 0.87 | RAB9A (0.65) | L3MBTL1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL9561524 | 0.84 | ALDH1A1 (0.51) | RAB9ASMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL25210162 | 0.84 | L3MBTL1 (0.57) | L3MBTL1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL20460467 | 0.83 | NPC1 (0.60) | L3MBTL1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL12456093 | 0.83 | L3MBTL1 (0.63) | L3MBTL1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL17670950 | 0.82 | L3MBTL1 (0.58) | L3MBTL1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL3409371 | 0.82 | HPGD (0.59) | L3MBTL1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL3369793 | 0.82 | L3MBTL1 (0.58) | L3MBTL1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL10645032 | 0.82 | L3MBTL1 (0.58) | L3MBTL1RAB9ASMN1; SMN2NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| CN-107849053-B | Spiro compounds | 里科瑞尔姆IP控股有限责任公司 | 2020-10-30 | — | — | CN | disclosed |
| US-8492437-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-7943643-B2 | Aryl substituted pyridines and the use thereof | PURDUE PHARMA L.P. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943643-B2 | Aryl substituted pyridines and the use thereof | PURDUE PHARMA L.P. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100048626-A1 | Aryl Substituted Pyridines and the Use Thereof | PURDUE PHARMA L.P. | 2010-02-25 | — | — | US | disclosed |
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED | 2009-12-10 | — | — | US | disclosed |
| US-7579367-B2 | Aryl substituted pyridines and the use thereof | PURDUE PHARMA L.P. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080194627-A9 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2008-08-14 | — | — | US | disclosed |
| CN-101115721-A | Indenyl derivatives and their use in the treatment of neurological diseases | GLAXO GROUP LTD (GB) | 2008-01-30 | — | — | CN | disclosed |
| US-20070010554-A1 | Aryl substituted pyridines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194627-A9 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1C | L3MBTL1 116/4885RAB9A 3343/4885SMN1; SMN2 7/4885 |
| US-20100048626-A1 | Aryl Substituted Pyridines and the Use Thereof | CACNA1S, CACNA1E, CACNA1C | L3MBTL1 129/4885RAB9A 3446/4885SMN1; SMN2 8/4885 |
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, INMT, INA | L3MBTL1 1592/4885RAB9A 1932/4885SMN1; SMN2 110/4885 |
| US-20070010554-A1 | Aryl substituted pyridines and the use thereof | CACNA1S, CACNA1E, CACNA1C | L3MBTL1 116/4885RAB9A 3343/4885SMN1; SMN2 7/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | L3MBTL1 1776/4885RAB9A 628/4885SMN1; SMN2 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.